Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of Anti-LILRB2 Antibody ES009 in Australia
SHANGHAI & SUZHOU, China & GERMANTOWN, Md.--(BUSINESS WIRE)--Elpiscience Biopharmaceuticals (“Elpiscienceâ€), a clinical-stage biopharmaceutical company dedicated…